Prostate Cancer Clinical Trial
Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
Summary
The purpose of this study is to utilize this technology in the early detection and staging of pathologic states within prostate cancer patients using the information obtained on mpMRI and serum biomarkers from the patient's blood (if collected). Ultimately, investigators hope to improve the diagnostic accuracy and treatment selection process for these patients. Applying the fusion software which adds mpMRI to ultrasound images in real time, to an otherwise clinically standard but non-targeted ultrasound-guided prostate biopsy procedure will help with accurate and early diagnosis of prostate cancer.
Eligibility Criteria
Inclusion Criteria:
Able to give informed consent
Male - age > 18
mpMRI within the previous 6 months (PIRADS 3,4,5, all stages of PCa)
Scheduled for TRUS biopsy for prostate lesion or mass
Exclusion Criteria:
Age under 18 years of age.
Female
Pre-existing blood dyscrasias
Inability to perform TRUS due to anal sphincter closure/surgery
Patients needing general anesthesia
Patients allergic to lidocaine
Patients allergic or unable to take antibiotics
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Tucson Arizona, 85724, United States More Info
Principal Investigator
How clear is this clinincal trial information?